Usher syndrome, a rare genetic disorder causing both hearing and vision loss, presents significant diagnostic and therapeutic challenges due to its complex genetic basis. The identification of reliable biomarkers for early detection and intervention is crucial for improving patient outcomes. In this study, we present a machine learning-based hybrid sequential feature selection approach to identify key mRNA biomarkers associated with Usher syndrome. Beginning with a dataset of 42,334 mRNA features, our approach successfully reduced dimensionality and identified 58 top mRNA biomarkers that distinguish Usher syndrome from control samples. We employed a combination of feature selection techniques, including variance thresholding, recursive feature elimination, and Lasso regression, integrated within a nested cross-validation framework. The selected biomarkers were further validated using multiple machine learning models, including Logistic Regression, Random Forest, and Support Vector Machines, demonstrating robust classification performance. To assess the biological relevance of the computationally identified mRNA biomarkers, we experimentally validated candidates from the top 10 selected mRNAs using droplet digital PCR (ddPCR). The ddPCR results were consistent with expression patterns observed in the integrated transcriptomic metadata, reinforcing the credibility of our machine learning-driven biomarker discovery framework. Our findings highlight the potential of machine learning-driven biomarker discovery to enhance the detection of Usher syndrome.

Usher syndrome (USH) is a rare genetic disorder affecting vision, hearing, and balance. Identifying reliable biomarkers is crucial for early diagnosis and understanding disease mechanisms. MicroRNAs (miRNAs), key regulators of gene expression, hold promise as biomarkers for USH. This study aimed to identify a minimal subset of miRNAs that could serve as biomarkers to effectively differentiate USH from controls. We employed ensemble feature selection techniques to select the top miRNAs appearing in at least three algorithms. Machine learning models were trained and tested using this subset, followed by validation on an independent 10% sample. Our approach identified 10 key miRNAs as potential biomarkers for USH. To further validate their biological relevance, we conducted pathway analysis, which revealed significant pathways associated with USH. Furthermore, our approach achieved high classification performance, with an accuracy of 97.7%, sensitivity of 98%, specificity of 92.5%, F1 score of 95.8%, and an AUC of 97.5%. These findings demonstrate that combining ensemble feature selection with machine learning provides a robust strategy for miRNA biomarker discovery, advancing USH diagnosis and molecular understanding.

Usher syndrome (USH) is an inherited disorder characterized by sensorineural hearing loss (SNHL), retinitis pigmentosa (RP)-related vision loss, and vestibular dysfunction. USH presents itself as three distinct clinical types, 1, 2, and 3, with no biomarker for early detection. This study aimed to explore whether microRNA (miRNA) expression in USH cell lines is dysregulated compared to the miRNA expression pattern in a cell line derived from a healthy human subject. Lymphocytes from USH patients and healthy individuals were isolated and transformed into stable cell lines using Epstein–Barr virus (EBV). DNA from these cell lines was sequenced using a targeted panel to identify gene variants associated with USH types 1, 2, and 3. Microarray analysis was performed on RNA from both USH and control cell lines using NanoString miRNA microarray technology. Dysregulated miRNAs identified by the microarray were validated using droplet digital PCR technology. DNA sequencing revealed that two USH patients had USH type 1 with gene variants in USH1B (MYO7A) and USH1D (CDH23), while the other two patients were classified as USH type 2 (USH2A) and USH type 3 (CLRN-1), respectively. The NanoString miRNA microarray detected 92 differentially expressed miRNAs in USH cell lines compared to controls. Significantly altered miRNAs exhibited at least a twofold increase or decrease with a p value below 0.05. Among these miRNAs, 20 were specific to USH1, 14 to USH2, and 5 to USH3. Three miRNAs that are known as miRNA-183 family which are crucial for inner ear and retina development, have been significantly downregulated as compared to control cells. Subsequently, droplet digital PCR assays confirmed the dysregulation of the 12 most prominent miRNAs in USH cell lines. This study identifies several miRNA signatures in USH cell lines which may have potential utility in Usher syndrome identification.

Background: The thioredoxin system (TrxS) is crucial for maintaining redox balance by regulating cellular thiol levels and is involved in various biological processes, including cancer progression. Thioredoxin reductase (TrxR), a key component of TrxS, reduces oxidized thioredoxin (Trx) using NADPH. This study investigates the inhibitory effects of 2-bromo-2-nitro-1,3-propanediol (Bronopol, BP), a preservative, on TrxR activity and its impact on cellular thiols and cell viability. Methods: Purified recombinant TrxR and noncancer and cancer cells were treated with different concentrations of BP and TrxR activity measured. BP-treated cells were examined for effects of BP on total cellular thiol level and GSH/GSSG ratio. Results: BP effectively inhibited TrxR in a dose-dependent manner, an effect that was reversible with dithiothreitol (DTT). BP treatment significantly reduced total thiol levels, decreased the GSH/GSSG ratio, and increased reactive oxygen species (ROS) in cells. Additionally, BP decreased cell viability and induced apoptosis, as indicated by morphological changes and increased c-fos mRNA expression. Conclusions: These findings highlight BP’s potential as a TrxR inhibitor and its cytotoxicity toward both noncancer and cancer cells. The observed effects—TrxR inhibition, thiol oxidation, GSH/GSSG imbalance, and ROS accumulation—may underlie BP’s cytotoxicity. Further research is needed to explore the precise molecular mechanisms by which BP exerts these effects.

Background: Usher syndrome (USH) is a rare genetic disorder that affects both hearing and vision. It presents in three clinical types—USH1, USH2, and USH3—with varying onset, severity, and disease progression. Existing diagnostics primarily rely on genetic profiling to identify variants in USH genes; however, accurate detection before symptom onset remains a challenge. MicroRNAs (miRNAs), which regulate gene expression, have been identified as potential biomarkers for disease. The aim of this study is to develop a data-driven system for the identification of USH using miRNA expression profiles. Methods: We collected microarray miRNA-expression data from 17 samples, representing four patient-derived USH cell lines and a non-USH control. Supervised feature selection was utilized to identify key miRNAs that differentiate USH cell lines from the non-USH control. Subsequently, a network model was constructed by measuring pairwise correlations based on these identified features. Results: The proposed system effectively distinguished between control and USH samples, demonstrating high accuracy. Additionally, the model could differentiate between the three USH types, reflecting its potential and sensitivity beyond the primary identification of affected subjects. Conclusions: This approach can be used to detect USH and differentiate between USH subtypes, suggesting its potential as a future base model for the identification of Usher syndrome.

Background/Objectives: Ovarian cancer is a heterogeneous malignancy with molecular subtypes that strongly influence prognosis and therapy. High-dimensional mRNA data can capture this biological diversity, but its complexity and noise limit robust subtype characterization. Furthermore, current classification approaches often fail to reflect subtype-specific transcriptional programs, underscoring the need for computational strategies that reduce dimensionality and identify discriminative molecular features. Methods: We designed a multi-stage feature selection and network analysis framework tailored for high-dimensional transcriptomic data. Starting with ~65,000 mRNA features, we applied unsupervised variance-based filtering and correlation pruning to eliminate low-information genes and reduce redundancy. The applied supervised Select-K Best filtering further refined the feature space. To enhance robustness, we implemented a hybrid selection strategy combining recursive feature elimination (RFE) with random forests and LASSO regression to identify discriminative mRNA features. Finally, these features were then used to construct a gene co-expression similarity network. Results: This pipeline reduced approximately 65,000 gene features to a subset of 83 discriminative transcripts, which were then used for network construction to reveal subtype-specific biology. The analysis identified four distinct groups. One group exhibited classical high-grade serous features defined by TP53 mutations and homologous recombination deficiency, while another was enriched for PI3K/AKT and ARID1A-associated signaling consistent with clear cell and endometrioid-like biology. A third group displayed drug resistance-associated transcriptional programs with receptor tyrosine kinase activation, and the fourth demonstrated a hybrid profile bridging serous and endometrioid expression modules. Conclusions: This pilot study shows that combining unsupervised and supervised feature selection with network modeling enables robust stratification of ovarian cancer subtypes.